Selank
- Focus & brain health
- Inflammation & immunity
The anxiety peptide — it matched the benzodiazepine medazepam across every anxiety scale used, and added a lift in drive and alertness that medazepam did not.
Read the published research →View COAs1 report
| Tested sample | Task number | Analysis date | Measured results | Report |
|---|---|---|---|---|
| 10 mg | 171226 | Jun 22, 2026 | Selank: 10.95 mg · Purity: 99.509% |
What Selank does
Selank is a synthetic extension of tuftsin, a natural immune peptide, lengthened at one end so tissue enzymes cannot chew it up quickly. Its defining result is a head-to-head against a benzodiazepine: in adults with generalised anxiety disorder or neurasthenia, it matched medazepam on the Hamilton, Zung and CGI scales, and only the Selank arm additionally showed antiasthenic and psychostimulant effects. Added on top of the benzodiazepine phenazepam in a second randomised trial, it brought the response forward in time and lowered phenazepam's own rated side effects — sedation, asthenia, impaired attention and memory — against phenazepam alone. There is no single receptor behind this: Selank blocks the enzymes that break down enkephalin in human plasma, shifts GABA signalling, and a single dose altered 45 of 84 neurotransmission genes in rat frontal cortex, so much of what is called its mechanism is a transcriptional signature rather than a defined target. The one quantified safety signal is cardiovascular: arterial pressure fell about 32% below baseline within minutes of intravenous injection in anaesthetised cats, recovering without a change in heart rate.
- Everyday anxiety without benzodiazepine sedation
- Calm focus rather than being dulled
- Attention and memory under stress
- Easing benzodiazepine side effects during a taper
- Mood and stress resilience
- Immune and inflammatory tone
Common areas of interest, not measured results. The findings below are the published data.
In a randomised comparative trial in 62 adults with generalised anxiety disorder or neurasthenia — 30 given Selank, 32 given the benzodiazepine medazepam — anxiolytic effects on the Hamilton, Zung and CGI scales were similar between arms, and only the Selank arm additionally showed antiasthenic and psychostimulant effects. Patients had a shortened serum leu-enkephalin half-life at baseline that correlated with illness duration and with the severity of anxiety, asthenia and autonomic symptoms; this parameter rose, with stronger positive correlations with anxiety level, during Selank treatment and chiefly in the generalised anxiety subgroup.3
In a randomised trial in 70 adults with anxiety-phobic, hypochondriacal and somatoform disorders, adding Selank to phenazepam (40 patients) rather than giving phenazepam alone (30 patients) brought the HDRS response forward in time and reduced UKU-rated side effects of the benzodiazepine — sedation, asthenia, attention and memory impairment, lengthened sleep, sexual disturbance, emotional indifference and orthostatism — both during co-administration and after the tranquilliser was withdrawn.4
In a placebo-controlled resting-state fMRI study of 52 healthy adults scanned before and 5 and 20 minutes after a single injection of Selank, Semax or placebo, functional connectivity between the right amygdala and a right-hemisphere fusiform, temporal and parahippocampal region differed both between groups and between scan conditions.15
For laboratory research use only. Not a drug, food, or cosmetic. Not for human or veterinary use, ingestion, or any form of consumption. Sold exclusively to qualified researchers.
